4579.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 08:15):

Stats
Dagens volum	95 100.00
Gjennomsnittsvolum	124 670
Markedsverdi	12.87B
EPS	¥0 ( 2024-02-14 )
Neste inntjeningsdato	( ¥0 ) 2024-05-12
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-39.69
ATR14	¥0.734 (0.12%)

Volum Korrelasjon

Lang: -0.01 (neutral)

Kort: -0.62 (weak negative)

Signal:(47.079) Neutral

RaQualia Pharma Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

RaQualia Pharma Inc. Korrelasjon - Valuta/Råvare

0.70
( moderate )

0.18
( neutral )

-0.09
( neutral )

0.47
( neutral )

-0.13
( neutral )

-0.73
( moderate negative )

RaQualia Pharma Inc. Økonomi

Annual	2023
Omsetning:	¥1.90B
Bruttogevinst:	¥1.48B (77.88 %)
EPS:	¥-14.98

FY	2023
Omsetning:	¥1.90B
Bruttogevinst:	¥1.48B (77.88 %)
EPS:	¥-14.98

FY	2022
Omsetning:	¥2.92B
Bruttogevinst:	¥2.69B (92.06 %)
EPS:	¥34.50

FY	2021
Omsetning:	¥2.78B
Bruttogevinst:	¥2.46B (88.45 %)
EPS:	¥7.20

Financial Reports:

No articles found.

RaQualia Pharma Inc.

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.